Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Accelerated Approval Should Be Less 'Wide Open,' Califf Says

Executive Summary

FDA should write more about its interpretation of regs and apply it more consistently across divisions, commissioner says.


Related Content

Sarepta Pressured FDA On Eteplirsen Due To ‘Dire’ Finances, Gave Investors Rosier Picture
FDA's Fears Realized: Sponsors Pitching Investors 'Sarepta Model'
Political Appointees Shouldn't Influence Approval Decisions, Califf Says
No More Sarepta-Like Development, FDA Officials Say
Accelerated Approval After Eteplirsen: A Lowered Bar Or A Unique Event?
Sarepta's Eteplirsen Approved After Contentious Internal Debate
FDA's Breakthrough Workload Will Be Eased By Hiring Reviewers With PDUFA VI Funds
Rare Disease Integration Into FDA Reviews Will Grow Under PDUFA VI
Accelerated Approval May Support Smaller Trials In Acute Diseases – FDA
Regulatory Flexibility Staring Contest: Will Industry Or FDA Blink First?


Related Companies